The Procter & Gamble Company announced that it is collaborating with Cleveland Clinic and Cleveland HeartLab to develop and commercialize a diagnostic and management solution for a recently-discovered heart disease biomarker. As part of the partnership, Cleveland HeartLab will develop a diagnostic test to measure blood levels of TMAO, while Cleveland Clinic will work with Procter & Gamble to develop an over-the-counter product that could help people manage their TMAO levels.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
163.8 USD | -0.04% |
|
-2.16% | +11.80% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.80% | 387B | |
+20.30% | 78.67B | |
-6.25% | 70.65B | |
-27.22% | 38.17B | |
-14.96% | 35.06B | |
+0.33% | 32.84B | |
+9.40% | 18.31B | |
+20.57% | 16.76B | |
+8.75% | 12.94B | |
+14.08% | 9.38B |
- Stock Market
- Equities
- PG Stock
- News Procter & Gamble Company
- Procter & Gamble Partners with Cleveland Clinic & Cleveland HeartLab to Develop Heart Disease Biomarker